This phase II trial is evaluating a new form of immunotherapy (xentuzumab) to see whether it enhances combination treatment with a chemotherapy drug (Everolimus) and hormone therapy drug (Exemestane) in patients with hormone receptor positive (HR+), HER2- breast cancer that has spread to other parts of the body.
This trial is treating patients with HR+ / HER2- Breast Cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Post-menopausal Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease
Participants in this trial will be randomised to receive either intravenous xentuzumab or placebo, in combination with oral everolimus and oral exemestane.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More